Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations. / Nygård, Lotte; Ahlborn, Lise B; Persson, Gitte F; Chandrananda, Dineika; Langer, Jonathan W; Fischer, Barbara M; Langer, Seppo W; Gabrielaite, Miglė; Kjær, Andreas; Rosenfeld, Nitzan; Mouliere, Florent; Østrup, Olga; Vogelius, Ivan R; Bentzen, Søren M.
In: PLoS ONE, Vol. 15, No. 4, e0231884, 2020.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations
AU - Nygård, Lotte
AU - Ahlborn, Lise B
AU - Persson, Gitte F
AU - Chandrananda, Dineika
AU - Langer, Jonathan W
AU - Fischer, Barbara M
AU - Langer, Seppo W
AU - Gabrielaite, Miglė
AU - Kjær, Andreas
AU - Rosenfeld, Nitzan
AU - Mouliere, Florent
AU - Østrup, Olga
AU - Vogelius, Ivan R
AU - Bentzen, Søren M
PY - 2020
Y1 - 2020
N2 - BACKGROUND: The overall aim was to investigate the change over time in circulating cell free DNA (cfDNA) in patients with locally advanced non-small cell lung cancer (NSCLC) undergoing concurrent chemo-radiotherapy. Furthermore, to assess the possibility of detecting circulating cell free tumor DNA (ctDNA) using shallow whole genome sequencing (sWGS) and size selection.METHODS: Ten patients were included in a two-phase study. The first four patients had blood samples taken prior to a radiation therapy (RT) dose fraction and at 30 minutes, 1 hour and 2 hours after RT to estimate the short-term dynamics of cfDNA concentration after irradiation. The remaining six patients had one blood sample taken on six treatment days 30 minutes post treatment to measure cfDNA levels. Presence of ctDNA as indicated by chromosomal aberrations was investigated using sWGS. The sensitivity of this method was further enhanced using in silico size selection.RESULTS: cfDNA concentration from baseline to 120 min after therapy was stable within 95% tolerance limits of +/- 2 ng/ml cfDNA. Changes in cfDNA were observed during therapy with an apparent qualitative difference between adenocarcinoma (average increase of 0.69 ng/ml) and squamous cell carcinoma (average increase of 4.0 ng/ml). Tumor shrinkage on daily cone beam computer tomography scans during radiotherapy did not correlate with changes in concentration of cfDNA.CONCLUSION: Concentrations of cfDNA remain stable during the first 2 hours after an RT fraction. However, based on the sWGS profiles, ctDNA represented only a minor fraction of cfDNA in this group of patients. The detection sensitivity of genomic alterations in ctDNA strongly increases by applying size selection.
AB - BACKGROUND: The overall aim was to investigate the change over time in circulating cell free DNA (cfDNA) in patients with locally advanced non-small cell lung cancer (NSCLC) undergoing concurrent chemo-radiotherapy. Furthermore, to assess the possibility of detecting circulating cell free tumor DNA (ctDNA) using shallow whole genome sequencing (sWGS) and size selection.METHODS: Ten patients were included in a two-phase study. The first four patients had blood samples taken prior to a radiation therapy (RT) dose fraction and at 30 minutes, 1 hour and 2 hours after RT to estimate the short-term dynamics of cfDNA concentration after irradiation. The remaining six patients had one blood sample taken on six treatment days 30 minutes post treatment to measure cfDNA levels. Presence of ctDNA as indicated by chromosomal aberrations was investigated using sWGS. The sensitivity of this method was further enhanced using in silico size selection.RESULTS: cfDNA concentration from baseline to 120 min after therapy was stable within 95% tolerance limits of +/- 2 ng/ml cfDNA. Changes in cfDNA were observed during therapy with an apparent qualitative difference between adenocarcinoma (average increase of 0.69 ng/ml) and squamous cell carcinoma (average increase of 4.0 ng/ml). Tumor shrinkage on daily cone beam computer tomography scans during radiotherapy did not correlate with changes in concentration of cfDNA.CONCLUSION: Concentrations of cfDNA remain stable during the first 2 hours after an RT fraction. However, based on the sWGS profiles, ctDNA represented only a minor fraction of cfDNA in this group of patients. The detection sensitivity of genomic alterations in ctDNA strongly increases by applying size selection.
KW - Adenocarcinoma/drug therapy
KW - Aged
KW - Aged, 80 and over
KW - Antineoplastic Agents/therapeutic use
KW - Carcinoma, Non-Small-Cell Lung/genetics
KW - Carcinoma, Squamous Cell/drug therapy
KW - Cell-Free Nucleic Acids/blood
KW - Chemoradiotherapy
KW - Female
KW - Humans
KW - Lung Neoplasms/genetics
KW - Male
KW - Middle Aged
KW - Pilot Projects
KW - Radiation, Ionizing
KW - Tomography, X-Ray Computed
U2 - 10.1371/journal.pone.0231884
DO - 10.1371/journal.pone.0231884
M3 - Journal article
C2 - 32343749
VL - 15
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 4
M1 - e0231884
ER -
ID: 247889847